Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, milestone payments, and complex royalty schedules make Cytokinetics filings notoriously dense. Whether you’re dissecting how a cardiac myosin activator advances through Phase III or estimating the company’s cash runway, combing through hundreds of pages can stall decisive action.
Stock Titan turns that obstacle into clarity. Our AI instantly delivers Cytokinetics SEC filings explained simply, mapping each section of the Cytokinetics annual report 10-K simplified to the questions investors actually ask. Need the latest Cytokinetics quarterly earnings report 10-Q filing? We surface R&D spend and partnership revenue in seconds. Looking for Cytokinetics insider trading Form 4 transactions or Cytokinetics Form 4 insider transactions real-time? Alerts arrive the moment EDGAR posts. You can even see trial-related surprises through our summaries of Cytokinetics 8-K material events explained. Key use cases include:
- Tracking Cytokinetics executive stock transactions Form 4 before clinical read-outs
- Comparing pipeline costs across quarters with our Cytokinetics earnings report filing analysis
- Reviewing Cytokinetics proxy statement executive compensation to align leadership incentives with drug-approval timelines
- Understanding Cytokinetics SEC documents with AI-generated plain-English notes
Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A and more—is captured in real time, then distilled by our expert models. Spend less time scrolling and more time deciding when trial milestones or insider moves signal opportunity.
Dr. Edward M. Kaye, a director of Cytokinetics Inc. (CYTK), reported a sale of 6,756 shares of the issuer's common stock on 09/02/2025 at a reported price of $50 per share, leaving him with 23,230 shares beneficially owned following the transaction. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
Cytokinetics, Inc. (CYTK) filed a Form 144 notifying a proposed sale of 4,300 common shares, estimated at an aggregate market value of $151,919.00, to be executed approximately on 09/02/2025 on NASDAQ. The securities were acquired as restricted stock units (RSUs) on 01/02/2024 and the filing indicates the broker handling the transaction is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states there were 119,657,156 shares outstanding for the class reported. No securities of the issuer were reported sold by the reporting person in the prior three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Insider sale reported: Director Robert A. Harrington sold 2,150 shares of Cytokinetics, Inc. (CYTK) on 09/02/2025 at $48.67 per share, reducing his direct holdings to 20,493 shares. The Form 4 indicates the sale was reported under a transaction code for a sale and the filing was signed by an attorney-in-fact. The form also marks a box indicating the transaction may have been made pursuant to a written plan.
Robert I. Blum, President & CEO and a director of Cytokinetics, Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 09/02/2025 at a reported price of $48.76 per share. After the transaction, Mr. Blum is shown as beneficially owning 378,108 shares directly and additionally reports indirect beneficial ownership of 2,083 shares held by each of two irrevocable trusts (The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust). The Form 4 was signed by an attorney-in-fact for Mr. Blum.
Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.
Cytokinetics Inc. (CYTK) reports a non-derivative equity award to director James M. Daly. On 08/19/2025 Mr. Daly received a non-qualified stock option to purchase 27,450 shares of common stock with an exercise price of $37.84 per share. The option becomes exercisable on 09/19/2025 and expires on 08/19/2035. Following the reported transaction, Mr. Daly beneficially owns 27,450 shares underlying the option as a direct position. The filing states this was an initial grant to a new director.
Insider transactions by Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics (CYTK), are reported on Form 4. On 08/19/2025 he exercised 2,000 non‑qualified stock options at an exercise price of $10.60 and concurrently sold 2,000 shares at $38.31. After these transactions he beneficially owned 140,610 shares. The filing shows 9,105 option shares remaining exercisable from the option series.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
